Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Launched by BASILEA PHARMACEUTICA · May 22, 2024
Trial Information
Current as of March 14, 2025
Available
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
About Basilea Pharmaceutica
Basilea Pharmaceutica is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for infectious diseases and cancer. With a strong commitment to addressing unmet medical needs, Basilea focuses on pioneering research and development of novel compounds, leveraging cutting-edge science to enhance patient outcomes. The company strives to bring groundbreaking treatments to market, supported by a robust pipeline and strategic partnerships, while adhering to the highest standards of quality and regulatory compliance in its clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
